KR20190021311A - 알츠하이머병의 치료 방법 - Google Patents

알츠하이머병의 치료 방법 Download PDF

Info

Publication number
KR20190021311A
KR20190021311A KR1020197000443A KR20197000443A KR20190021311A KR 20190021311 A KR20190021311 A KR 20190021311A KR 1020197000443 A KR1020197000443 A KR 1020197000443A KR 20197000443 A KR20197000443 A KR 20197000443A KR 20190021311 A KR20190021311 A KR 20190021311A
Authority
KR
South Korea
Prior art keywords
subject
antibody
body weight
administering
weeks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197000443A
Other languages
English (en)
Korean (ko)
Inventor
브랜든 필립 부트
제프리 조지프 세비니
레슬리 루진 윌리엄스
Original Assignee
바이오겐 인터내셔널 뉴로사이언스 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이오겐 인터내셔널 뉴로사이언스 게엠베하 filed Critical 바이오겐 인터내셔널 뉴로사이언스 게엠베하
Priority to KR1020237040938A priority Critical patent/KR20230165883A/ko
Publication of KR20190021311A publication Critical patent/KR20190021311A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
KR1020197000443A 2016-06-07 2017-06-06 알츠하이머병의 치료 방법 Ceased KR20190021311A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237040938A KR20230165883A (ko) 2016-06-07 2017-06-06 알츠하이머병의 치료 방법

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662346818P 2016-06-07 2016-06-07
US62/346,818 2016-06-07
US201662435531P 2016-12-16 2016-12-16
US62/435,531 2016-12-16
PCT/EP2017/063711 WO2017211827A1 (en) 2016-06-07 2017-06-06 Methods for treating alzheimer's disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237040938A Division KR20230165883A (ko) 2016-06-07 2017-06-06 알츠하이머병의 치료 방법

Publications (1)

Publication Number Publication Date
KR20190021311A true KR20190021311A (ko) 2019-03-05

Family

ID=59067640

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020197000443A Ceased KR20190021311A (ko) 2016-06-07 2017-06-06 알츠하이머병의 치료 방법
KR1020237040938A Ceased KR20230165883A (ko) 2016-06-07 2017-06-06 알츠하이머병의 치료 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020237040938A Ceased KR20230165883A (ko) 2016-06-07 2017-06-06 알츠하이머병의 치료 방법

Country Status (12)

Country Link
US (2) US20200308259A1 (enExample)
EP (1) EP3464350A1 (enExample)
JP (3) JP2019517540A (enExample)
KR (2) KR20190021311A (enExample)
CN (3) CN114931635A (enExample)
AU (2) AU2017276656A1 (enExample)
BR (1) BR112018075300A2 (enExample)
CA (1) CA3026598A1 (enExample)
IL (1) IL263433B2 (enExample)
MA (1) MA45149A (enExample)
MX (1) MX2018015022A (enExample)
WO (1) WO2017211827A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201827467A (zh) 2016-11-03 2018-08-01 比利時商健生藥品公司 焦穀胺酸類澱粉蛋白－β之抗體及其用途
EP3696192A1 (en) 2019-02-15 2020-08-19 Consejo Superior De Investigaciones Científicas Therapeutic target and monoclonal antibodies against it for the diagnosis and treatment of alzheimer´s disease
JOP20210265A1 (ar) 2019-03-26 2023-01-30 Janssen Pharmaceutica Nv الأجسام المضادة لبيروغلوتامات أميلويد بيتا واستخداماتها
CN110511276A (zh) * 2019-08-13 2019-11-29 王跃驹 植物作为宿主在表达Aducanumab抗体中的应用
WO2021081101A1 (en) * 2019-10-22 2021-04-29 Biogen Ma Inc. Anti-beta-amyloid antibody for treating alzheimer's disease
KR20230039734A (ko) 2020-07-23 2023-03-21 오타이르 프로테나 리미티드 항-Aβ 항체
KR102321601B1 (ko) * 2020-11-19 2021-11-05 주식회사 휴런 뇌 영상을 이용한 알츠하이머병의 생물학적 분류 장치 및 방법
US20240270830A1 (en) * 2021-06-07 2024-08-15 Biogen Ma Inc. Methods for treating alzheimer's disease
WO2023055733A1 (en) * 2021-09-30 2023-04-06 The Scripps Research Institute Compounds for reducing neuroinflammation
KR20240101629A9 (ko) * 2021-11-19 2025-12-10 에이피 바이오사이언시스, 아이엔씨. Cd137을 표적화하는 이중특이적 항체 및 항암 면역요법을 위한 이의 용도

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2468770T3 (en) * 2006-07-14 2018-03-12 Ac Immune Sa Humanized antibody to amyloid beta
ES2641897T3 (es) * 2007-01-05 2017-11-14 University Of Zurich Procedimiento para proporcionar moléculas de unión y diana específicas de una enfermedad
AU2011315181B2 (en) 2010-10-11 2016-07-28 Biogen International Neuroscience Gmbh Human anti-tau antibodies
RS60388B1 (sr) * 2012-10-15 2020-07-31 Medimmune Ltd Antitela usmerena na beta-amiloid
CN105979962A (zh) * 2012-12-07 2016-09-28 比奥根国际神经科学公司 使用抗Aβ抗体减少脑淀粉样蛋白斑块的方法
US9598484B2 (en) 2012-12-21 2017-03-21 Biogen Ma Inc. Human anti-tau antibodies
JP6685912B2 (ja) * 2014-02-08 2020-04-22 ジェネンテック， インコーポレイテッド アルツハイマー病治療方法
MA41115A (fr) * 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer

Also Published As

Publication number Publication date
CN114796481A (zh) 2022-07-29
US20200308259A1 (en) 2020-10-01
JP2022145965A (ja) 2022-10-04
AU2017276656A1 (en) 2018-12-13
EP3464350A1 (en) 2019-04-10
CN114931635A (zh) 2022-08-23
JP2019517540A (ja) 2019-06-24
MX2018015022A (es) 2019-08-14
KR20230165883A (ko) 2023-12-05
US20220281963A1 (en) 2022-09-08
IL263433B1 (en) 2023-11-01
JP2025160337A (ja) 2025-10-22
IL263433B2 (en) 2024-03-01
MA45149A (fr) 2019-04-10
WO2017211827A1 (en) 2017-12-14
CA3026598A1 (en) 2017-12-14
AU2024216442A1 (en) 2024-10-17
IL263433A (en) 2019-01-31
CN109476730A (zh) 2019-03-15
BR112018075300A2 (pt) 2019-04-30

Similar Documents

Publication Publication Date Title
JP2025182058A (ja) アルツハイマー病の治療法
US20220281963A1 (en) Methods for treating alzheimer's disease
KR20220084095A (ko) 알츠하이머병의 치료를 위한 항-베타-아밀로이드 항체
JP2024540294A (ja) アルツハイマー病を治療するための方法
NZ788486A (en) Methods for treating Alzheimer's disease
WO2022261026A2 (en) Methods for treating alzheimer's disease
WO2026015877A1 (en) Fluid biomarker

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190107

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200605

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220729

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20230629

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20220729

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20231128